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The management of cough in adults with respiratory and non-respiratory illnesses is suboptimal and
based mostly on clinical opinions rather than evidence. A systematic review was carried out assessing all
trials in adult patients with respiratory and non-respiratory diseases (excluding cancer) that had chronic
cough as primary or secondary outcome. A total of 1177 trials were retrieved and 75 met the criteria for
inclusion in the review. The vastmajoritywere in patientswith asthma and chronic obstructive pulmonary
disease (COPD). Coughwas the primary outcome in less than one-quarter of the studies. Themeasurement
of cough was variable, mostly using unvalidated scales or being part of an overall ‘symptoms’ score.
Positive results were overall seen with the use of corticosteroids, leukotriene receptor antagonists, mast
cell stabilizers, ipratropium bromide, neltenexine, iodinised glycerol and lidocaine. Speech pathology
training and symptom monitoring through SMS messages (accompanied by treatment adjustments) have
also shownpromise. Evidence for established anti-tussive agents such as codeinewas scarce, with positive
studies from the 1960s, whilst more recent studies showed no effect in patients with COPD. Many studies
had conﬂicting results. It is imperative that the management of cough and its evidence base be improved,
using higher quality research designs and with cough being the primary outcome of trials.
 2010 Elsevier Ltd. All rights reserved.Introduction
Cough is a common and often difﬁcult problem seen by primary
care physicians and other clinicians. Perhaps if we had an easy
answer and a treatment that always or even usually worked we
would not ﬁnd chronic cough so frustrating. This literature review
provides a summary of the 75 papers found to deal with chronic
cough therapy. It will not be a surprise to many that antitussives
have limited value in controlling chronic cough but read on to see
what else is available and in what situations they may work.
Educational aims
 To present the most common mechanisms for chronic cough.
 To review the evidence for the efﬁcacy and effectiveness of the
most commonly used classes of drugs to treat chronic cough.
 To present evidence for each type of therapy by disease
e.g. COPD, asthma, acute respiratory infections.sly published article. DOI of
: þ44 161 306.
(A. Molassiotis).
rved.1. Background
Cough is a common symptom in respiratory (non-malignant)
diseases1 and related non-respiratory conditions, such as nasal
disease or gastro-oesophageal reﬂux disease (GORD/GERD)]. Cough
may either be productive (wet) producing purulent or mucoid
sputum or non-productive (dry). Cough can be further divided into
three categories based on duration: acute, lasting less than three
weeks; sub-acute, lasting three to eight weeks; and chronic, lasting
more than eight weeks.2,3 Common causes of non-malignant cough
include viral upper respiratory tract infections (the commonest by
far), airway disease, including asthma and chronic obstructive
pulmonary disease; gastro-oesophageal reﬂux disease (GORD),
nasal disease, bronchiectasis and chronic infections. Persistent
cough can be distressing to patients, leading to depression (in up to
53% of patients),4,5 insomnia, vomiting, exhaustion and rib frac-
tures.6,7 Cough has a signiﬁcant human and socioeconomic burden,
as it is linked with absenteeism fromwork, impaired quality of life
and effects in daily activities.8 A number of reviews outlining
managementoptions1e3,8,9 exist, but there is limitedcomprehensive
systematic synthesis and assessment of effective management
strategies currently available in adult patients, as most systematic
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on children, whooping cough or antibiotic use in adults with pro-
longed cough. Furthermore, the management of cough is highly
variable in clinical practice, and some of the reasons for this may
include the unsystematic evaluation of causes of cough, the frequent
use of non-speciﬁc cough treatments and the clinicians’ insufﬁcient
knowledge in cough management.10 A synthesis of evidence could
assist in addressing some of these issues.
Hence there is a need to examine the existing evidence in cough
research in respiratory and non-respiratory illnesses in order to
highlight areas needing further research development, provide an
understanding of the level of evidence for interventions used to
manage cough and aid clinicians in their clinical decision-making.
1.1. Objective
The objective of this review was to determine the effective-
ness of pharmacological and non-pharmacological/non-invasive
interventions in the relief of cough in non-malignant respiratory
and non-respiratory conditions in adult patients experiencing
chronic cough.
1.2. Types of studies
Randomised Controlled Trials (with blinding)
Controlled Clinical Trials (quasi randomised trials, trials with or
without blinding and randomisation not mentioned, trials with
a comparative arm).1.3. Types of participants
Adult patients described as experiencing either acute, sub-acute
or chronic cough; presence of cough (either productive (wet) cough
producing purulent or mucoid sputum or non-productive (dry)
cough without purulent or mucoid sputum) due to non-malignant
respiratory and non-respiratory diseases with a high prevalence
of cough, including interstitial lung disease (ILD), bronchiectasis;
Chronic Obstructive Pulmonary Disease (COPD)/Chronic Obstruc-
tive Airways Disease (COAD); pulmonary oedema; lung abscess;
emphysema; asthma; bronchitis; cardiac disease, including
congestive heart failure (CHF), chronic heart failure and dilated
cardiomyopathy; extra thoracic causes of cough including reﬂux
disease, nasal disease and Ace-inhibitor related cough. Patients
included in the studies could be treated in any clinical setting.
Interventions should have a comparator group (placebo, another
substance or usual care). Studies designed to examine effects on
cough directly or as a proxy for improvement of an underlying
disorder would be included.
1.4. Exclusion criteria
The following disease types were excluded:
Upper respiratory tract infection e bacterial and viral/chest
infections; common cold; post infection cough, habitual cough;
enlarged uvula; stress; acute sinusitis, lung cancer. Cough reﬂex
sensitivity studies and animal studies were also excluded. Paedi-
atric studies were also excluded, unless there was a mixed sample
of children and adults.
1.5. Types of intervention
Pharmacological interventions: Any medicinal product or
substance as classiﬁed by the EU directive 2001/83/EEC “any
substance or combination of substances which may beadministered to human beings or animals with a view to making
a diagnosis or to restoring, correcting or modifying physiological
function in human beings or animals is likewise considered
a medicinal product.”
Non-pharmacological interventions were deﬁned according to
EU Directive 2001/83/EEC as ‘any interventions that are not clas-
siﬁed as medicinal products’ and invasive and non-invasive inter-
ventions, such as complementary therapies, physiotherapy,
education, behavioural approaches and self-management.
1.6. Types of outcome measures
The primary outcome was subjective measures of cough
frequency, severity ordistress onvalidated and reliable scales such as
visual analoguescales, numerical rating scales, andcategorical scales.
Secondary outcomes: Objective improvement in cough; Quality
of life measured by validated and reliable instruments; Side-effects;
Patient withdrawal from trials.
1.7. Search methods for identiﬁcation of studies
A scoping search using broad terms and several databases, as
well as consultationwith clinicians contributed to the development
of the search terms for this review. The electronic databases
searched included:
MEDLINE (1966eApril 2009)
EMBASE (1980eApril 2009)
CINAHL (1980eApril 2009)
British Nursing Index (1985eApril 2009)
PsychINFO (1985eApril 2009)
Science Citation Index Expanded (1985eApril 2009)
AMED (Allied and Complementary Medicine) (1985eApril
2009)
Cochrane Pain, Palliative and Supportive Care Trails Register
(Winter 2009 issue) Cochrane Database of Systematic Reviews
(CDSR) (Winter 2009 issue)
The Cochrane Central Register of Controlled Trials (CENTRAL)
(Winter 2009 issue)
Database of Abstracts of Reviews of Effectiveness (DARE)
(Winter 2009 issue)
PEDRO (physiotherapy) database (to April 2009)
The Index to Scientiﬁc and Technical Proceedings (to January
2009)
Conference Papers Index (to April 2009)
National Research Register (to April 2009)
SIGLE (System for Information on Grey Literature) (1980eApril
2009)1.8. Search strategy
The search terms included cough, respiratory illnesses (as
a general term andwith speciﬁc diagnoses), generic classes of drugs
(anti-tussives, cough suppressants, opioids, topical anaesthetics,
NMDA receptor antagonists, antihistamines, bronchodilators,
steroids, antimuscarinics, aromatic inhalations) followed by
speciﬁc drugs identiﬁed in the scoping exercise, complementary
therapies (with individual therapies also included), physiotherapy,
exercise movement technique, self-management, self-care, respi-
ratory therapy, non-pharmacological interventions. In total, 108
terms were combined together with cough and respiratory disease
diagnoses alongside with a published strategy for identifying
randomised controlled trials.11 A complete search strategy is
available from the authors.
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The reference lists of all relevant studieswere checked for further
relevant studies. Authors of main studies were contacted to ﬁnd out
about any unpublished or grey literature. The Index to Scientiﬁc and
Technical Proceedings, the Conference Papers index and theNational
Research Register were additionally searched for grey literature.
1.10. Language
Studies in English language or with an available English trans-
lation were included.
1.11. Methods of the review
1.11.1. Selection of studies
Titles and abstracts of identiﬁed studies were reviewed for
relevance by two reviewers. The full text of all potentially relevant
studies was assessed by two reviewers. Any disagreements were
resolved after discussion with the rest of the reviewing team.
1.11.2. Assessment of methodological quality
Methodological quality was assessed independently by two
reviewers. A Jadad score (Oxford Quality Index) was assigned for
each study.12 This is a score ranging from 0 to 5, with points
assigned for randomisation, blinding and withdrawals/dropouts,
with a higher score representing a higher quality trial.
1.11.3. Data extraction
A data extraction form was designed. One reviewer extracted
the data from each paper, and a second reviewer evaluated the data
extracted from all papers, reaching agreement in relation to the
quality of the data and the Jadad score assigned. Agreement was
achieved with each assessor assessing a small number of papers
independently and then comparing the data extraction and scores
with the other assessor, discussing also ways of being consistent in
data extraction. A third reviewer checked a random sample for
consistency. The following details were included: Publication
details; Study aim; Study design; Sample size and patient charac-
teristics; Adverse events; Method of assessing cough; Type of
intervention; Outcome measures; Withdrawals and dropouts;
Handling of missing data; Study results; Follow-up data; Any
economic data; and any patient narrative comments.
1.11.4. Data analysis
Reviewed studies were grouped into disease types and the
effectiveness of speciﬁc strategies within each disease population
assessed. A narrative synthesis is used to analyse the data obtained.
2. Results
1177 articles were retrieved and assessed through the search
strategy. These included primarily results from searches in the
electronic databases (n ¼ 1164; 62 included) as well as 31 articles
from hand searches (9 included) and 10 from additional sources
(4 included). Approaching key authors in the ﬁeld has resulted in no
more articles. After excluding duplicates, articles related to acute
chest infections, vaccines, malignancies, reviews and those which
had no outcome related to cough, 75 trials were included in this
review (see Table 1 for indicative studies and Online Table under
Supplementary Material for detailed description of all studies
reviewed).13e86
The 75 trials included in the review had a total sample of 11,738
adult patients (mean of 156 patients/trial), however if the very
large single trial63 on smoking cessation is excluded (as it skews theresults), the mean sample per trial was 78 subjects, ranging from 8
to 5887 subjects. The majority of studies were conducted in adult
patients with asthma and COPD patients.
Twenty-three trials were identiﬁed in adult patients with
asthma (n ¼ 1508, mean sample size ¼ 65, range 8e235). Steroids
were the most common drug tested as a cough therapy, and all
studies were positive, particularly with beclomethasone15,16,18,20
and budesonide.30 Mast cell stabilizers were also shown to be
effective, including disodium cromoglycate,24 lodoxadine87 and
nedocromil sodium (two trials with positive results26,28) and two
larger trials with negative results.27,29 Leukotriene receptor antag-
onists were also effective (2 trials) as was the use of a Th2 cytokine
inhibitor (1 trial).25,32,35 Two different ayuverdic herbs were
equally effective with salbutamol and deriphylline used in one
trial,33 although the trial was of poor quality, as was another
positive herbal trial using ginger.19 Theophylline did not show any
improvements in cough in one trial.34 A study whereby patients
reported PEF values to researchers daily through SMSmessages and
researchers subsequently contacted patients to adjust medication
or arrange hospital appointments showed signiﬁcantly lower cough
scores than the control group in a small study of 16 patients.31
Eight trials were identiﬁed in relation to adult patients with
bronchitis (total n¼ 731). All but two trials had a sample size of less
than 80 subjects. While the use of low dose N-acetylcysteine38,39
and budenoside40 were negative, effective treatments included
epinastine,41 ipratropium bromide over fenspiride42 theophylline45
and iodinised glycerol.43,44
Eighteen trials included adult patients with COPD (n ¼ 8013
subjects), with amean of 125 subjects/trial (excluding the single very
large smoking cessation trial). Negative studies included the use of
budesonide,47 codeine,48 nesosteine61 and oxitropium bromide (in
addition to theophylline).62 Positive resultswere shownwith regards
to fenspiride,50 ﬂuticasone,51 formoterol,52 neltenexine,58e60 heli-
cidine (a biological extract prepared from the snail Helix pomatia
L.),53 oxtriphylline64 and a high dose (1200 mg) N-acetylcysteine.56
While lidocaine 4 ml had an equivalent effect to bronchodilators
(but fewer side-effects)55 and ipratropium bromide was also equiv-
alent to another drug of the same class, that of metaproterenol.54 In
a large trial of 5887 smokers, a smoking cessation programme led to
signiﬁcant decreases in cough symptoms as well as in the use of
inhaled ipratropium bromide.63
Five trials have tested a proton pump inhibitor in the manage-
ment of cough in adult patients with reﬂux disease (n ¼ 258
subjects; mean of 52 patients/trial). While esoprazole and ome-
prazole showed negative results in one trial each,69,72 lansopra-
zole70 and omeprazole71,73 have provided positive results over
placebo. Morphine (5 mg) in one trial66 and speech pathology
training in another trial67 were also effective treatments in relation
to idiopathic cough. Allergic rhinoconjuctivitis was the focus of one
trial only, in which the tested antihistamine (loratadine) in a small-
scale study was shown to be effective.13 Benzonatate was equiva-
lent to amixture that contained codeine in one trial of patients with
asthmatic bronchitis and emphysema36 as was codeine in a small
trial of 10 patients.68 Moguisteine and dextromethophran were
shown to be equivalent in a trial of 124 patients.78 A large trial of
codeine was also effective in a dose of 60 mg46 as was neltenexine
in two further trials.79,80 Sinecod linctus, a common over-the-
counter cough medication, was no more effective than a small dose
of codeine in one trial.86
3. Discussion
Some of the key and overarching issues identiﬁed through this
systematic review include the limited amount of research directed
speciﬁcally to the management of chronic cough, the signiﬁcant
Table 1
Indicative interventions for non-malignant cough [for a description of all studies see Online Table under Supplementary material].
Author Date Country Study Design Sample, size Treatment (dose) Outcome Measures Results Conclusions/Comments Jadad score
Ribeiro et al.,
2007 Brazil18
RCT
Double Blind
N ¼ 64 (42M/22F) Chloroﬂuorocarbon-
beclomethasone
(1500 mg/d) or
placebo for
2 weeks.
Decrease in daily
cough scores during
the 2-week
treatment period
(Patient symptom,
diary and visual
analogue scale
(Primary)
36/42 patients (82%) in active group had
complete resolution of cough. 8 showed no
improvement (18%). Cough cessation was
observed in 3 patients (15%) in the placebo
group, whilst cough persisted in
17 patients (85%).
Signiﬁcant improvement in
cough symptoms in patients
treated with
chloroﬂuorocarbon-
beclomethasone
compared with placebo.
4
Patients had
cough>8 weeks.
Secondary
outcomes:
Duration of
cough, respiratory
questionnaire,
bronchoprovocation
testing (BPT)
with methaholine
and allergy testing
Median duration
of cough similar in both
groups (P ¼ 0.9).
Difference in cough diaries
and VAS before and
after beclomethasone
compared with before
and after placebo (difference
of differences,1.0 95% CI, 0.4e1.5;
P < 0.002 for diaries,
difference of differences
1.1, 95% CI 0.6e1.8, P < 0.01 for VAS).
Comparison of symptom
diaries with VAS data
for the placebo and
control groups at the end of the protocol
(P ¼ 0.001)
Signiﬁcant difference
in numbers
of patients
experiencing resolution
of cough when treated with
chloroﬂuorocarbon-
beclomethasone
compared to placebo.
10 patients
were smokers.
No correlation between cough diaries and
questionnaires (r ¼ 0.12, P ¼ 0.07) or
BPT (r ¼ 0.23, P ¼ 0.06).
Nicolis et al.,
1962 Italy46
RCT
Double Blind
N ¼ 184
(No gender info)
Study 1: Codeine
(30mg qid)
or placebo for 5 days,
crossed over after a 3 day
washout period (n ¼ 43).
Cough
(primary)
Study 1 and 2 failed to show any signiﬁcant
difference between placebo and codeine.
Statistically signiﬁcant
difference in number
of coughs in patients
treated with a single
dose of codeine
(60mg) compared
to placebo.
However, 2 studies
with lower codeine
dosages over longer
timeframe failed
to identify a signiﬁcant
effect on cough.
2
N ¼ 19 (14M/5F) Study 2: Codeine
(30mg qid)
or placebo for 8 days
crossed over every
3 days (n ¼ 56)
Study 3 reported a signiﬁcant difference in
number of coughs in patients treated with
codeine compared to placebo
(group 1: 6.4  1.2 V 11.7  1.5, P < 0.001;
group 2: 8.2  1.9 V 13.5  1.9, P < 0.001;
Group 3: 9.8  1.6 VS. 14.5  1.9, P < 0.001).
Authors give
no information
about withdrawals
or adverse events.
Study 3: Codeine (60mg)
or placebo single application.
(3 separate groups of patients).
Authors also provide
a graphical comparison of
mean number of coughs/h at 3 different
time-points for 33 patients
(group3). Difference
between codeine and placebo
signiﬁcant at 3 h
and 4 h after codeine
administration 2 h after
administration ¼ P > 0.05, 3 h after
administration ¼ P < 0.01, 4 h after
administration ¼ P < 0.001).
Trend towards difference
in the mean number
of coughs in heavier
coughing patients treated
with codeine (NS).
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Smith et al.,
2006 UK48
RCT Double
blind, placebo
controlled
Cross-over trial
N ¼ 19 (14M/5F) Codeine (60 mg b.i.d.)
or placebo.
Cough frequency
(primary) Citric acid
thresholds, subjective
cough measures (VAS).
Median rate of cough (combined night
and day scores) was lower during treatment with
codeine (6.41 coughs/h, IQR 3.86e9.10, P ¼ 0.02
compared with baseline) compared to placebo
(7.22 c/h, IQR 4.42e10.40, P ¼ 0.03 compared
with baseline) and baseline
(8.27 c/h, IQR 5.94e11.67). 4% reduction in
cough rate was observed for codeine compared
with placebo (mean difference ¼ 1.1 cs/h,
95% CI, 0.89e1.25 cs/h).
No signiﬁcant improvement in cough
frequency in patients treated with
codeine compared to placebo.
4
Log 10 transformed cough rates showed a sig.
difference between baseline, placebo and codeine
rates (repeat-measures ANOVA, F ¼ 4.97, df ¼ 2,
P ¼ 0.02). Differences between baseline, codeine
and placebo treatments was seen in day cough
scores 9f ¼ 3.72, df ¼ 2, P ¼ 0.05), but not in
night scores (F ¼ 0.56, df ¼ 2, P0.48). Difference
between subjective baseline cough scores and
day and night scores NS (F ¼ 0.453, df ¼ 2,
P ¼ 0.59; and F ¼ 0.68, df ¼ 2,
P ¼ 0.50 respectively).
No SD between daytime codeine and baseline
VAS scores P ¼ 0.11. Difference between codeine
and placebo, P ¼ 0.96. No SD between baseline,
placebo or codeine (P ¼ 0.25). No signiﬁcant
correlations between the change in time spent
coughing and the change in cough score
(day r ¼ 0.07, P ¼ 0.78, night ¼ 0.17, P ¼ 0.48)
or change in VAS (day r ¼ 0.07, P ¼ 0.79, night
r ¼ 0.30, P ¼ 0.24).
Chong et al., 2005
Taiwan55
RCT Double blind N ¼ 127
(85M/42F)
Lidocaine (4 ml N ¼ 62) or
Bronchodilator (N ¼ 65)
Effectiveness
(primary)
Improvement in cough severity scores in both
groups 1 h post inhalation compared to baseline
(Lidocaine score ¼ 3 versus 8, P < 0.01,
Bronchodilator score ¼ 3 versus 8, P < 0.01.).
P ¼ 0.44 for difference between Lidocaine and
bronchodilators.
Signiﬁcant improvement in cough
severity scores in patients treated
with Lidocaine or Bronchodilators
for short term cough suppression.
5
Cough severity
score, comparison
of adverse effects.
228 adverse events reported.
Signiﬁcantly more patients
experienced tremors and
palitations whilst using
Bronchodilators compared to
those Lidocaine. Signiﬁcantly more
patients using lidocaine reported
oropharyngeal numbness and a bitter
taste compared to bronchodilator
patients (P < 0.01).
Morice et al.,
2007 UK66
RCT N ¼ 27 (9M/18F) Morphine (5mg) b.i.d.
or placebo for 4 weeks.
Change in Leicester
Cough Questionnaire
for Chronic Cough
(primary), daily cough
diary, citric
cough challenges.
Daily cough diary showed a
signiﬁcant reduction
in mean cough scores on morphine
P < 0.01 compared with baseline.
Signiﬁcant improvement in mean
cough scores in patients treated
with morphine.
4
Double Blind Patients
had persistent
cough > 3 months.
AE: adverse reactions; NS: not signiﬁcant; SD: signiﬁcant differences; h ¼ hour.
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and the small samples used. Among the 75 studies reviewed, only
about one-quarter (N ¼ 20) of the studies used ‘cough’ as a primary
outcome. The vast majority of studies were focused on efﬁcacy of
treatment in relation to respiratory illnesses, with cough being
a secondary outcome. Very few studies reported sample size
calculations, hence it is not possible to ascertain whether negative
results are due to a Type II error or not. Quality scores were also
variable, although it is encouraging to see that more recent studies
have been assigned higher Jadad scores in this review.
The measurement of cough in the reviewed studies has been
particularly problematic. The vast majority of the trials have used
patient diaries, cough counts, and patient self reports, largely
unvalidated methods for measuring cough. Often cough has been
only a small component of ‘symptoms’ and included as part of
a number of other symptoms (such as dyspnoea) assessed together.
Only a couple of trials have used a validated method of measuring
cough, such as the Leicester Cough Questionnaire. Some studies
assessed cough frequency, some others cough intensity and others
cough distress/discomfort. While these data are important, each
study describes a separate facet of the cough symptom experience:
a better approach, arguably, would be to address all three param-
eters together as each provides a different and complementary
perspective (a frequent mild and not distressing cough is a different
experience, for example, compared with an occasional severe and
distressing cough).
Nevertheless, some treatments have shown consistently positive
results (with varying levels of effect) in speciﬁc patient groups,
including corticosteroids, leukotriene receptor antagonists, mast cell
stabilizers, ipratropium bromide, neltenexine, ionised glycerol and
lidocaine. In GORD, proton pump inhibitors may be effective in indi-
vidual patients, but a relevant systematic review speciﬁc to GORD
suggests that data are insufﬁcient to support their use,88 while for
allergic rhinoconjuctivitis the use of antihistamines may be appro-
priate. The trials, however, often present mixed results that do not
allow forﬁrmconclusions to bedrawn(suchas themast cell stabilizer
nedocromil) or positive evidence comes from a single small study
withnoreplication (suchasTh2cytokine inhibitor).Also, theexample
of codeine (by far one of the commonest prescriptions for cough) is
interesting as it is generally considered to be the anti-tussive towhich
novel treatments should be compared. Early small scale and poor
quality trials in the 1960s/70s show positive results, while more
recent higher quality trials suggest no effect of codeine over placebo;
whether codeine should be the comparator when designing trials of
new medications is increasingly in question. Benzonatate, moguis-
teine and dextromethophran (the latter often included in over-the-
counter cough mixtures) also showed possible effects, but again the
evidence base for these drugs is small.
Non-pharmacological trials are scarce, with only three trials
identiﬁed, and only two (speech pathology training and use of SMS
messages to monitor symptoms) showing positive results. Speech
pathology training could be a useful adjunct to pharmacological
treatments, particularly as coughing has the potential to traumatise
the upper airways (i.e. the vocal cords). More work should be
directed in this promising area. Monitoring symptoms through
technology (mobile phones/internet) is another area that has
shown improvements, and this is amethod that can have important
self-management and health service utilisation implications. This is
an area of increasing research focus, and studies have already
started demonstrating the potential of such applications.89,90
It is clear that the treatment options for cough are far from
satisfactory, and have been described as an unmet need for the
cough patient.91 Future research should focus more appropriately
in providing concrete evidence for the management of this
common and distressing symptom. Cough should be measured asthe primary outcome with the use of validated methods that
consider all dimensions of the cough experience. Both subjective
and objective measures should be used, as they have the potential
to capture both patient perception and independent evidence of
efﬁcacy.92 Patients should be selected carefully for inclusion,
avoiding heterogeneity in terms of concurrent respiratory disease,
smoking status and other clinical characteristics that may affect the
results (i.e. concurrent maintenance treatments). More research
should explore the impact of cough on psychosocial status, quality
of life and daily activities. Also, it is unclear from the trials reviewed
what the duration of any treatment should be, as studies for the
same drug have used different durations for the intervention. Many
of the studies showing statistically signiﬁcant positive effects have
managed to change the cough by 15e20%; whether this is a clini-
cally important difference and whether patients can notice such
a small difference is unclear. This issue needs further exploration in
the literature. There should also be a better balance between testing
non-speciﬁc and speciﬁc anti-tussives in the future.
With the lack of clarity in the assessment and management of
cough as described above and elsewhere,91,93 it is not surprising
that clinical guidelines have focused to date more on principles of
treatment rather than on much needed explicit guidance for clin-
ical decision-making, and are mostly based upon expert opinion
rather than evidence base. Such difﬁculties have been highlighted
in the latest updated guidelines from the American College of Chest
Physicians.92
Idiopathic cough, accounting for a signiﬁcant number of patients
seen in secondaryand tertiarycare, has been the focus of only 3 trials
with a total of 158 subjects enrolled. A 20% of patients with cough
maypresentwithmore thanoneaggravating factor,94 and this group
of patients may need a more complex management regime before
symptom resolution is achieved, but few trials have focused on this
population. Combinations of treatments may need to be developed,
including both pharmacological and non-pharmacological
approaches. Furthermore, there is an urgent need for more high
quality research to build the evidence base around themanagement
of cough in respiratory illness, more attention from the physicians
and higher investment from the industry. New preparations are in
phase II or III trials (e.g. NOP1 agonists, bradykinin B2 or GABA
receptor antagonists, among others).93 Amitryptiline, gabapentin
and carbamazepine are experimental options that could have a role
in themanagement of cough91 supported by case study reports. It is
to be hoped that some better tested and improved cough medica-
tions will enter the market in the next few years.
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Educational questions
Answer the following questions:
1. Chronic cough is deﬁned as daily coughing of which duration?
a. Cough lasting at least three weeks
b. Cough lasting eight weeks or more
c. Cough lasting three months or more
d. Cough lasting three months or more in two consecutive
years.
2. Chronic cough affects which of the following?
a. sleep
b. absenteeism
c. changes in daily activities
d. quality of life
e. all of the above
3. Which of the following medications have been shown to be
helpful in decreasing cough across several conditions?
a. Codeine
b. Inhaled corticosteroids
c. Antihistamines
d. Theophyllines
4. Cough is easily measured using standardized, well validated
and commonly used measures.
a. True
b. False
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